HighVista Strategies
HighVista Strategies reported 136 stocks worth $381M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are DBC (9.0%), RVMD (2.5%) and ABVX (2.3%). Compared with Q2 2026, the fund opened new positions in GMAB, MANE and CTNM, added to TNGX, TARS and COGT, trimmed RVMD, ABVX and PCVX and sold out of ALMS, MLYS and EYPT.
Latest filing: what HighVista Strategies did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() DBC Invsc DB Commodity Index | $34.2M | 9.0% | 1.1M | No change | 8 of 8 | |
| 2 | ![]() RVMD Revolution Medicines Inc | $9.4M | 2.5% | 46K | −21K (−31%) | 8 of 8 | |
| 3 | ![]() ABVX Abivax SA | $8.6M | 2.3% | 87K | −26K (−23%) | 8 of 8 | |
| 4 | ![]() PCVX Vaxcyte Inc | $8.1M | 2.1% | 142K | −7,632 (−5%) | 8 of 8 | |
| 5 | ![]() GMAB Genmab A/s | $8.1M | 2.1% | 226K | New position | 1 of 8 | |
| 6 | ![]() RLAY Relay Therapeutics Inc | $7.4M | 1.9% | 409K | −97K (−19%) | 6 of 8 | |
| 7 | ![]() TNGX Tango Therapeutics Inc | $7.2M | 1.9% | 288K | +28K (+11%) | 3 of 8 | |
| 8 | ![]() TARS Tarsus Pharmaceuticals Inc | $7.1M | 1.9% | 90K | +3,372 (+4%) | 6 of 8 | |
| 9 | ![]() IMVT Immunovant Inc | $7M | 1.8% | 206K | −72K (−26%) | 7 of 8 | |
| 10 | ![]() COGT Cogent Biosciences Inc | $6.7M | 1.8% | 210K | +21K (+11%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() ALMS Alumis Inc | $5.6M | 200K |
![]() MLYS Mineralys Therapeutics Inc | $2.3M | 86K |
![]() EYPT Eyepoint Pharmaceuticals Inc | $2.2M | 156K |
![]() RBC RBC Bearings Inc | $2.1M | 3,223 |
![]() RKT Rocket Companies Cla A | $2M | 126K |
🔒 Free account: see all 30.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →HighVista Strategies 13F FAQ
What does HighVista Strategies own?
HighVista Strategies reported 136 stocks worth $381M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are DBC (9.0%), RVMD (2.5%) and ABVX (2.3%). The table above lists every position in the filing (the top 10 without an account).
What did HighVista Strategies buy and sell in Q3 2026?
Compared with Q2 2026: 24 new positions, 48 added to, 63 trimmed and 35 sold out. New positions include GMAB, MANE and CTNM. It sold all of ALMS, MLYS and EYPT.
When will HighVista Strategies file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is HighVista Strategies's portfolio worth?
The Q3 2026 filing reports $381M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.



























